Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) Shares Purchased by Jane Street Group LLC

Jane Street Group LLC raised its holdings in Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 1,064.4% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 345,092 shares of the company’s stock after acquiring an additional 315,456 shares during the quarter. Jane Street Group LLC owned 0.48% of Kiniksa Pharmaceuticals worth $8,624,000 as of its most recent filing with the SEC.

Other institutional investors also recently made changes to their positions in the company. Braidwell LP grew its holdings in shares of Kiniksa Pharmaceuticals by 40.6% in the 3rd quarter. Braidwell LP now owns 2,894,513 shares of the company’s stock worth $72,334,000 after acquiring an additional 836,210 shares during the period. Rubric Capital Management LP boosted its position in Kiniksa Pharmaceuticals by 10.2% during the second quarter. Rubric Capital Management LP now owns 2,419,103 shares of the company’s stock worth $45,165,000 after purchasing an additional 223,094 shares in the last quarter. Parkman Healthcare Partners LLC grew its holdings in Kiniksa Pharmaceuticals by 16.7% in the third quarter. Parkman Healthcare Partners LLC now owns 755,244 shares of the company’s stock valued at $18,874,000 after purchasing an additional 108,102 shares during the last quarter. FMR LLC increased its position in shares of Kiniksa Pharmaceuticals by 36,925.0% in the third quarter. FMR LLC now owns 696,810 shares of the company’s stock valued at $17,413,000 after buying an additional 694,928 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Kiniksa Pharmaceuticals by 31.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 664,040 shares of the company’s stock worth $12,398,000 after buying an additional 157,741 shares during the last quarter. 53.95% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. JPMorgan Chase & Co. increased their price objective on shares of Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, November 5th. Evercore ISI raised their price objective on shares of Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Finally, Jefferies Financial Group started coverage on Kiniksa Pharmaceuticals in a research report on Friday, September 13th. They set a “buy” rating and a $40.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $36.60.

Insider Activity

In other news, CFO Mark Ragosa sold 8,969 shares of the company’s stock in a transaction on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the completion of the sale, the chief financial officer now directly owns 22,958 shares in the company, valued at $492,449.10. This represents a 28.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, COO Eben Tessari sold 17,000 shares of the company’s stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $26.87, for a total value of $456,790.00. Following the sale, the chief operating officer now owns 109,975 shares of the company’s stock, valued at approximately $2,955,028.25. The trade was a 13.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 44,592 shares of company stock valued at $1,110,364 over the last quarter. Company insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Price Performance

Kiniksa Pharmaceuticals stock opened at $20.20 on Friday. The stock has a market capitalization of $1.46 billion, a P/E ratio of -144.29 and a beta of 0.27. Kiniksa Pharmaceuticals, Ltd. has a 12-month low of $16.56 and a 12-month high of $28.15. The firm’s 50-day moving average is $23.25 and its two-hundred day moving average is $23.05.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last announced its earnings results on Tuesday, October 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.17). The firm had revenue of $112.21 million for the quarter, compared to analyst estimates of $111.51 million. Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The firm’s revenue was up 67.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.20) EPS. As a group, analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 EPS for the current year.

Kiniksa Pharmaceuticals Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.